Neuren Pharmaceuticals (ASX:NEU) has announced the global expansion of its partnership with US company Acadia Pharmaceuticals for DAYBUE (trofinetide).
Acadia held the rights in North America, where DAYBUE was recently approved for the treatment of Rett Syndrome.
Under the expanded agreement, Neuren has received an upfront payment of US$100 million, with the potential for milestone payments of up to US$427 million and royalties on net sales outside North America.
The company expects US DAYBUE sales of US$45 to US$55 million in the third quarter of 2023.
Neuren CEO Jon Pilcher said, “We are very pleased to be able to expand our highly successful partnership with Acadia. The unique knowledge and expertise that the Acadia team has built from the successful development and commercialisation of DAYBUE in the United States, as well as the established supply chain, places them in the ideal position to achieve the optimum outcome globally for all stakeholders.
"We have also enhanced the position for NNZ-2591, adding the exciting potential to further increase its value through Acadia in Rett and Fragile X. We very much look forward to continuing to collaborate with Acadia as we all strive to make a difference in neurodevelopmental disorders, which have such urgent unmet need.”